Results 191 to 200 of about 384,919 (304)
Ovarian macrophage depletion reverses OHSS resistance in estrildid finches and exacerbates OHSS symptoms in rats. Activating macrophage GPR183 alleviates OHSS by reducing pro‐inflammatory factors, increasing immunomodulatory molecules, remodeling CD44/SDC4‐mediated communication, and restoring immune homeostasis.
Xiaofei Yan +11 more
wiley +1 more source
Expanding horizons of intravitreal anti-vascular endothelial growth factor therapy in retinal diseases. [PDF]
Singh S, Kala U, Bamel A, Agarwal M.
europepmc +1 more source
A high‐performance 3D scaffold integrating rGO and SHEDs is developed to overcome impaired healing in diabetic bone defects. By driving extracellular matrix remodeling, rGO creates a pro‐angiogenic niche that significantly accelerates in vitro vascular network formation.
Can Zhang +12 more
wiley +1 more source
Serial aqueous VEGF analysis for predicting anti-VEGF treatment outcomes in neovascular glaucoma from diabetic retinopathy: a prospective analysis. [PDF]
Joo T, Joo JH.
europepmc +1 more source
Brown adipocyte sheets are engineered to protect the heart against myocardial ischemia–reperfusion injury by restraining ferroptosis. Upon transplantation onto the cardiac surface, they improve cardiac function, limit infarction and fibrosis, and enhance angiogenesis.
Lifu Sun +6 more
wiley +1 more source
Anti-vascular endothelial growth factors in retinal and choroidal diseases - Present landscape. [PDF]
Kannan NB +3 more
europepmc +1 more source
A biomimetic, fiber‐reinforced hydrogel (FE‐PDA@Fib/Gel‐TG) that enables dual‐phase cranial defect repair. The system provides: instant hemostasis in the early stage, and sustained co‐delivery of pro‐angiogenic and osteogenic signals for synergistic vascularized bone regeneration.
Lingbin Che +9 more
wiley +1 more source
Dopamine D2 Receptor Agonists as Modulators of VEGF-A-Driven Angiogenesis: Mechanisms, Clinical Evidence, and Translational Opportunities. [PDF]
Akkanapally V +6 more
europepmc +1 more source
This study addresses the rapid renal clearance of anti‐HER2 nanobodies by developing specialized liposomal carriers. It details the formulation of dual modified liposomes, demonstrating how PEGylation preserves structural integrity and cell‐penetrating peptides enhance cellular interaction.
Giulia Pander +14 more
wiley +1 more source

